← Leaderboards
Fatemeh Sadat Majedi
Symphony Biosciences, Inc.
$1,389,904
Attributed
$2,380,221
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $992.7K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$2,380,221 · 1
By mechanism
R44$2,380,221 · 1
Top collaborators
- Dashtimoghadam Erfan2 shared
Most similar at Symphony Biosciences, Inc.
Same institution · by research overlap
- Dashtimoghadam Erfan$990,318
Others in their field
Other Rising Stars on “Adjuvant”
- Warwick Britton · University Of Sydney$10,964,476
- Philip Felgner · University Of California-Irvine$10,234,165
- Gregory Sorenson · University Of Maryland Baltimore County$9,161,697
- Li Liang · University Of California-Irvine$7,511,446
- Bruxanne El-Kammash · University Of Chicago$7,281,050
- Nicolas Collins · Vaccine Formulation Institute (Ch) Ltd$6,937,118
Research focus
AdjuvantAdverse EffectsAffectAlginatesAntibodiesAutoimmuneBiocompatible MaterialsBiocompatible PolymerBiodegradable PolymerBiological SciencesBiomedical EngineeringBiopsyBreast Cancer ModelCancer Infiltrating T CellsCanis FamiliarisCaringCar T Cell TherapyCellsCertificationCessation Of LifeChemotherapyClinical TrialsCytokine Release SyndromeAbscopal Effect
Grant awards (3)
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer$987,911
R44 · FY2025 · CA
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer$992,724
R44 · FY2024 · CA
Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer$399,586
R44 · FY2023 · CA · contact PI